HEALTHSTAT NEWS
STAT+: Pharmalittle: We’re reading about a hepatitis B drug, CVS returns Lilly obesity drug to formularies, and more
The article discusses upcoming public visibility of drug prices under Trump's most-favored-nation deals, highlighting three new drugs (Baxfendy, Awiqli, and Veppanu). CVS Health is reintroducing Eli Lilly's obesity drug Zepbound to formularies and removing coverage restrictions on Lilly's new weight loss pill Foundayo.
Mentioned
Related Signal
Adjacent reporting
- Full list of prescription drugs - including cholesterol-busting medication taken by millions - that could see massive price cuts under Trump's new deal
- France to partially reimburse weight-loss drugs for obesity patients
- STAT+: Ahead of ASCO, all eyes on pancreatic cancer
- Welcome to the Injection Age
- STAT+: Trump’s drug-pricing deals set to be tested by new product launches
- BTW | Goop Kitchen, Ozempic Breath, Hotspan